Language

English

Publication Date

1-1-2026

Journal

Vaccine

DOI

10.1016/j.vaccine.2025.127959

PMID

41319397

PMCID

PMC13105150

PubMedCentral® Posted Date

4-24-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

Introduction: Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is being used to mitigate disease in the current global mpox outbreak, but a global vaccine shortage may limit large scale vaccination.

Methods: Participants were randomized 1:1:1 to receive two doses of MVA-BN administered 28 days apart: intradermal (ID) 2 × 107 TCID50 (2 × 107 ID), ID 1 × 107 TCID50 (1 × 107 ID), or standard dose subcutaneous (SC) 1 × 108 TCID50 (1 × 108 ID). The primary objective was non-inferiority testing of each ID regimen compared to the standard SC regimen using vaccinia virus plaque reduction neutralizing titer assay (PRNT) geometric mean titers (GMT) at Day 43 (2 weeks post-second vaccination). Secondary objectives were non-inferiority testing of individual peak humoral immune responses, comparison of humoral immune responses, vaccinia virus-specific PRNT half-life (t½), and safety.

Results: Day 43 non-inferiority by PRNT GMT was established for the 2 × 107 ID regimen but not the 1 × 107 ID regimen. The 2 × 107 ID regimen was also non-inferior to the SC dose at Days 15 and 29, prior to the second dose; the 1 × 107 ID regimen did not meet the non-inferiority criteria at any point post-vaccination. The three study regimens had similarly high seroconversion rates and similar anti-vaccinia PRNT half-lives. Most participants experienced injection site and systemic reactogenicity of moderate severity or less and only mild unsolicited adverse events (mostly skin discoloration and nodules at the injection site).

Conclusion: The 2 × 107 ID regimen, but not the 1 × 107 ID regimen, was non-inferior to the SC regimen on Day 43. The study supports use of the 2 × 107 ID regimen if needed.

Keywords

Humans, Female, Male, Injections, Intradermal, Adult, Antibodies, Viral, Middle Aged, Vaccinia virus, Immunogenicity, Vaccine, Vaccination, Young Adult, Antibodies, Neutralizing, Injections, Subcutaneous, Immunity, Humoral, Smallpox Vaccine, Immunization Schedule, Adolescent, MVA-BN, vaccinia, mpox, clade, intradermal, dose-de-escalation

Comments

Clinicaltrials: govNCT05512949.

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.